SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025).

Authors

Francisco Ayala de la Peña, Silvia Antolín Novoa, Joaquín Gavilá Gregori, Lucía González Cortijo, Fernando Henao Carrasco, María Teresa Martínez Martínez, Cristina Morales Estévez, Agostina Stradella, María Jesús Vidal Losada, Eva Ciruelos

Published in

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. Nov 29, 2025. Epub Nov 29, 2025.

Abstract

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. As a result of the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages. In recent years, locoregional and systemic therapies have increasingly been directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates, have also improved outcomes in some patient subgroups. This clinical practice guideline for early-stage breast cancer (updated in 2025) is based on a systematic review of relevant studies and on the consensus of experts from the Spanish Breast Cancer Research Group (GEICAM), Spanish Collaborative Group for the Study, Treatment and Other Experimental Strategies in Solid Tumors (SOLTI), and Spanish Society of Medical Oncology (SEOM).

PMID:
41317270
Bibliographic data and abstract were imported from PubMed on 30 Nov 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.